MEI Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Christine A. White, M.D., has decided to retire and thus does not intend to stand for reelection at the Company’s fiscal year 2023 annual meeting of stockholders after a seven-year tenure as chair of the board and 12 years total serving as a director. Charles V. Baltic III, J.D., who has served on the board since 2011, has been elected to replace Dr. White as chair of the board. Dr. White’s retirement and Mr. Baltic’s assumption of the chair are effective as of the Company’s fiscal year 2023 annual meeting of stockholders.

“On behalf of the board and management, I would like to thank Christine for her unwavering dedication and strategic guidance during her 12-year tenure on the board of directors,” said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. “She is a remarkable person and an oncology biopharmaceutical thought leader who has provided invaluable leadership, grounded insight and clear direction, which has significantly supported MEI’s growth and the advancement of its oncology drug candidates. We sincerely wish her all the best in her retirement.”

Dr. Gold continued: “Although we will miss Christine, we are very fortunate to have Charles as our chair elect. We look forward to working with Charles in his new capacity as board chair to leverage his history and familiarity with MEI. His extensive industry and professional experience will be invaluable in advancing our mission to improve outcomes for patients with cancer through our efforts to develop and commercialize novel, best-in-class therapies.”

Mr. Baltic has served as a director of MEI Pharma since October 2011 and as chair of the nominating and governance committee since 2012. He also serves as a director and chair of the board of AssayQuant Technologies, Inc., a private company focused on kinase-based assay drug development technologies exclusively licensed to AssayQuant by the Massachusetts Institute of Technology. Mr. Baltic most recently served as executive vice president and COO of SIDIS Corp. from 2019 to 2021, overseeing the sale of the Propel Labs flow cytometry business to Thermo Fisher Scientific in February 2021. Since 1996, Mr. Baltic has held several healthcare investment banking positions, most recently at Needham & Company, LLC as managing director and co-head of healthcare banking until 2019 and as senior advisor from 2019 to 2022. Mr. Baltic also served on the U.S. Securities and Exchange Commission’s Advisory Committee on small and emerging growth companies from 2013 to 2015.